rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer
    sub title: data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
  title info:
    title: Initial experience with CDK four / six inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER two negative breast cancer
  name:
    name part: Schneeweiss, Andreas
    name part: 1961-
    role:
      role term: creator
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Ettl, Johannes
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Lüftner, Diana
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Beckmann, Matthias W.
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Belleville, Erik
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Fasching, Peter A.
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Fehm, Tanja
    name part: 1971-
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Geberth, Matthias
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Häberle, Lothar
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Hadji, Peyman
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Hartkopf, Andreas D.
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Hielscher, Carsten
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Huober, Jens
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Ruckhäberle, Eugen
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Janni, Wolfgang
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Kolberg, Hans Christian
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Kurbacher, Christian M.
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Klein, Evelyn
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Lux, Michael P.
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Müller, Volkmar
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Nabieva, Naiba
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Overkamp, Friedrich
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Tesch, Hans
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Laakmann, Elena
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Taran, Florin-Andrei
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Seitz, Julia
    name part: 1981-
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Thomssen, Christoph
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Untch, Michael
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Wimberger, Pauline
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Wuerstlein, Rachel
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Volz, Bernhard
    role:
      role term: VerfasserIn
    role:
      role term: aut
  name:
    name part: Wallwiener, Diethelm
    role:
      role term: VerfasserIn
  type of resource: text
  abstract: Purpose - Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor-positive, HER2-negative (HR + HER2-) breast cancer (BC). However, real-world data on the implementation of therapy usage, efficacy, and toxicity have not yet been reported. - Methods - The PRAEGNANT registry was used to identify advanced HR + HER2- BC patients (n = 1136). The use of chemotherapy, ET, everolimus + ET, and CDK4/6i + ET was analyzed for first-line, second-line, and third-line therapy. Progression-free survival (PFS) and overall survival (OS) were also compared between patients treated with CDK4/6i + ET and ET monotherapy. Also toxicity was assessed. - Results - CDK4/6i + ET use increased from 38.5% to 62.7% in the first 2 years after CDK4/6i treatment became available (November 2016). Chemotherapy and ET monotherapy use decreased from 2015 to 2018 from 42.2% to 27.2% and from 53% to 9.5%, respectively. In this early analysis no statistically significant differences were found comparing CDK4/6i + ET and ET monotherapy patients with regard to PFS and OS. Leukopenia was was seen in 11.3% of patients under CDK4/6i + ET and 0.5% under ET monotherapy. - Conclusions - In clinical practice, CDK4/6i + ET has been rapidly implemented. A group of patients with a more unfavorable prognosis was possibly treated in the real-world setting than in the reported randomized clinical trials. The available data suggest that longer follow-up times and a larger sample size are required in order to identify differences in survival outcomes. Studies should be supported that investigate whether chemotherapy can be avoided or delayed in this patient population by using CDK4/6i + ET.
  note: Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
  note: Gesehen am 15.02.2021
  classification: 33
  identifier: https://doi.org/10.1016/j.breast.2020.08.011
  identifier: https://www.sciencedirect.com/science/article/pii/S0960977620301648

role term: aut

name part: Wallwiener, Markus
name part: 1980-
role:
  role term: VerfasserIn
role:
  role term: aut

name part: Brucker, Sara Y.
role:
  role term: VerfasserIn
role:
  role term: aut

place:
  place term: xx
date issued: 2020
issuance: monographic

language term: eng

form: remote
extent: 8

topic: Abemaciclib

topic: Advanced breast cancer

topic: CDK4/6

topic: Chemotherapy

topic: Endocrine therapy

topic: Metastatic

topic: Palbociclib

topic: Ribociclib

title info:
  title: Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer
name:
  name part: Schneeweiss, Andreas, 1961 -
origin info:
  publisher: 2021
identifier: (DE-627)175365548X

title info:
  title: The breast
name:
  name part: Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
origin info:
  publisher: Amsterdam [u.a.] : Elsevier, 1992
physical description:
  extent: Online-Ressource
identifier: 1532-3080
identifier: (DE-627)320475042
identifier: (DE-600)2009043-2
identifier: (DE-576)103868151
part:
  text: 54(2020), Seite 88-95

name:
  name part: Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
part:
  text: volume:54
part:
  text: year:2020
part:
  text: pages:88-95
part:
  text: extent:8

record content source: DE-627
record creation date: 210215
record change date: 20250323014414.0
record identifier: 1748263293
language of cataloging:
  language term: ger